Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)12,172.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.61m
  • 1 Year change0.85%
  • Beta0.3656
Data delayed at least 20 minutes, as of May 16 2024 16:19 BST.
More ▼

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5,9626,4056,398
Total Receivables, Net11,9359,9238,795
Total Inventory5,4244,6998,983
Prepaid expenses1,6171,3291,512
Other current assets, total116237556
Total current assets25,05422,59326,244
Property, plant & equipment, net10,5029,44910,171
Goodwill, net20,04819,82019,997
Intangibles, net38,08939,30742,387
Long term investments1,6771,1421,237
Note receivable - long term529592504
Other long term assets22874102
Total assets101,11996,483105,363
LIABILITIES
Accounts payable3,2672,5502,824
Accrued expenses8,8618,3038,079
Notes payable/short-term debt515350387
Current portion long-term debt/capital leases4,8855,1921,506
Other current liabilities, total13,0149,8989,798
Total current liabilities30,54226,29322,594
Total long term debt23,22223,69028,888
Total debt28,62229,23230,781
Deferred income tax2,8442,9446,206
Minority interest232119
Other liabilities, total5,3456,4988,388
Total liabilities61,97659,44666,095
SHAREHOLDERS EQUITY
Common stock388387387
Additional paid-in capital35,18835,15535,126
Retained earnings (accumulated deficit)3,5671,4953,755
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity39,14337,03739,268
Total liabilities & shareholders' equity101,11996,483105,363
Total common shares outstanding1,5501,5501,549
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.